Key Updates
YOLO advanced 2.11% to $3.39 since the January 8th report, marking its third consecutive positive session and extending the recovery from the post-executive order selloff. The ETF has now gained 5.28% over five days, demonstrating technical stabilization around the $3.20-$3.25 support zone. YTD performance stands at +2.72%, though the 1-month decline of 13.08% reflects the continued digestion of December's volatility. The 6-month surge of 57.67% remains intact, confirming the structural uptrend driven by policy reform expectations remains fundamentally sound despite profit-taking dynamics.
Current Trend
YOLO is establishing a recovery pattern following the December 18-31 correction that saw the ETF decline 33% from post-announcement highs. The current price of $3.39 represents a 36% recovery from the December 31st low of $3.31, with the five-day gain of 5.28% suggesting momentum is rebuilding. The ETF remains 57.67% above its six-month baseline, indicating the medium-term uptrend remains intact. Technical support has formed around $3.20-$3.25, while resistance likely exists at $3.50-$3.60 based on recent trading ranges. The YTD gain of 2.72% positions YOLO modestly ahead of the broader market in early 2026, though significantly below the 85% peak gains achieved in mid-December before the executive order announcement.
Investment Thesis
The investment thesis for YOLO centers on federal cannabis policy reform creating a structural transformation in the U.S. cannabis industry's economics and capital access. The reclassification from Schedule I to Schedule III eliminates Section 280E tax burdens that have subjected cannabis businesses to effective tax rates of 60-90%, potentially reducing rates to the 20% range seen in other industries. This tax relief could unlock billions of dollars across the $32-34 billion state-regulated cannabis industry operating in 40 states. Beyond taxation, rescheduling opens pathways to traditional banking services, institutional capital investment, and federally funded research that were previously prohibited. The Medicare CBD pilot program launching in April 2025 represents a potential catalyst for pharmaceutical industry engagement and revenue diversification. With approximately $2.6 billion in accumulated tax liabilities across the top eight U.S. multistate operators from 2019-September 2025, the financial impact of 280E elimination would be immediately material to cash flows and profitability.
Thesis Status
The thesis remains fundamentally intact but faces implementation timeline uncertainty. President Trump's December 18th executive order directing cannabis rescheduling represents the "clearest federal signal on cannabis policy to date" according to AdvisorShares portfolio manager Dan Ahrens. However, the order includes no specific timeline, and Alliance Global Partners notes that a final rule by year-end would be critical for cannabis companies to secure 2025 tax savings. The 26.8% selloff in YOLO on announcement day reflects "buy the rumor, sell the news" dynamics and investor skepticism about whether rescheduling will actually occur, as reported by The Wall Street Journal. The thesis evolution now depends on regulatory implementation speed and the 30-day public comment period outcome, with the Medicare pilot program in April serving as a near-term proof point for federal commitment.
Key Drivers
The primary catalyst remains implementation of the Schedule III reclassification, with timing uncertainty representing the key variable. Wall Street analysts emphasize that year-end finalization would enable 2025 tax savings under Section 280E relief. The Medicare CBD pilot program launching in April 2025 affects approximately 34 million Medicare Advantage beneficiaries and could attract major pharmaceutical companies seeking federally insured revenue streams, according to CNBC reporting. Industry margin compression represents a structural headwind, with U.S. cannabis gross margins declining approximately 10 percentage points since 2021, making this "the most margin-compressed period the legal cannabis industry has ever seen." State-level enforcement dynamics create operational complexity, as evidenced by New York City's closure of over 1,600 illegal shops since 2024, which both protects licensed operators and highlights regulatory fragmentation challenges.
Technical Analysis
YOLO exhibits a classic post-capitulation recovery pattern following the December 18-31 correction. The ETF established a near-term bottom at $3.31 on December 31st, representing a 33% decline from post-announcement highs. The subsequent three-session advance of 2.11% to $3.39, combined with the five-day gain of 5.28%, suggests accumulation at support levels. The 6-month performance of +57.67% confirms the medium-term uptrend remains structurally intact despite short-term volatility. Key technical levels include support at $3.20-$3.25 (December lows) and resistance at $3.50-$3.60 (recent consolidation zone). The 1-month decline of 13.08% reflects profit-taking dynamics but has not violated the six-month uptrend channel. Volume patterns during the recovery suggest institutional re-engagement, though lighter than the December spike. The YTD gain of 2.72% positions YOLO in neutral territory for 2026, requiring a move above $3.50 to confirm continuation of the recovery phase.
Bull Case
- Section 280E Tax Elimination Creates Immediate Cash Flow Impact: Rescheduling to Schedule III will eliminate tax burdens that currently subject cannabis businesses to effective tax rates of 60-90%, potentially reducing rates to the 20% range and unlocking billions across the $32-34 billion industry, with the top eight U.S. multistate operators holding approximately $2.6 billion in accumulated tax liabilities. Source: WSJ, Source: Forbes
- Medicare Pilot Program Opens Pharmaceutical Revenue Pathway: The April 2025 Medicare CBD pilot program affecting 34 million beneficiaries could attract major pharmaceutical companies seeking federally insured revenue streams, with CMS Administrator indicating insurers have agreed to consider CBD coverage at no charge for eligible patients. Source: CNBC, Source: Axios
- Institutional Capital Access Transformation Expected: Schedule III status will enable cannabis companies to access traditional banking services and institutional investment previously prohibited, with industry experts indicating the sector's valuation "could double or triple" due to increased institutional access and liquidity. Source: CNBC, Source: Dutchie PR
- Merger and Acquisition Activity Expected to Accelerate: Analysts believe reclassification could create merger and acquisition opportunities as improved economics and capital access enable industry consolidation, with rescheduling potentially restarting congressional conversations around the SAFER Banking Act. Source: Morningstar
- Research Funding and Clinical Development Unlocked: Schedule III classification will facilitate federally funded clinical research and randomized controlled trials previously difficult to conduct, validating pharmaceutical cannabinoid development strategies and potentially expanding medical applications beyond current uses. Source: NYT, Source: DeFloria PR
Bear Case
- Implementation Timeline Uncertainty Creates Policy Risk: The executive order includes no specific timeline for rescheduling completion, with the 30-day public comment period and regulatory process creating uncertainty about whether final rules will be implemented in time for companies to secure 2025 tax savings, as investor skepticism drove the 26.8% selloff on announcement day. Source: WSJ, Source: Morningstar
- Industry Margin Compression at Historic Levels: U.S. cannabis gross margins have declined approximately 10 percentage points since 2021, making this "the most margin-compressed period the legal cannabis industry has ever seen," with operational pressures potentially offsetting tax relief benefits in the near term. Source: Morningstar
- Rescheduling Does Not Legalize Cannabis Federally: The reclassification to Schedule III does not legalize or decriminalize cannabis at the federal level, meaning state laws will continue to govern use and individuals will remain imprisoned on cannabis-trafficking charges while investors profit, limiting the scope of industry transformation. Source: Guardian, Source: NYT
- Political Opposition from Republican Lawmakers: The rescheduling move faced opposition from 22 Republican senators and 26 House Republicans, creating potential legislative obstacles and indicating the policy shift may not have broad political support necessary for comprehensive reform beyond executive action. Source: Morningstar
- State Regulatory Fragmentation Creates Operational Complexity: New York City's closure of over 1,600 illegal cannabis shops since 2024 and ongoing legal challenges to enforcement operations highlight the fragmented regulatory environment, with slow rollouts of licensed dispensaries (only 15 by June 2023 compared to Colorado's 200 in its first six months) creating market inefficiencies. Source: Business Insider